Literature DB >> 24759601

Appropriateness of administrative data for vaccine impact evaluation: the case of pneumonia hospitalizations and pneumococcal vaccine in Brazil.

S Sgambatti1, R Minamisava2, E T Afonso1, C M Toscano3, A L Bierrenbach3, A L Andrade3.   

Abstract

Ten-valent pneumococcal conjugate vaccine (PCV10) was recently introduced into the Brazilian Immunization Programme. Secondary data are used as a measurement of community-acquired pneumonia (CAP) burden, but their completeness and reliability need to be ascertained. We performed probabilistic linkage between hospital primary data from active prospective population-based surveillance (APS) and hospital secondary data from the Hospital Information System administrative database of the National Unified Health System (SIH-SUS). Children aged 2-23 months hospitalized during January-December 2012 were identified. Incidence rates of hospitalized CAP were estimated. Agreement of case identification was measured by kappa index. A total of 1639 (26%) CAP cases were identified in APS and 1714 (35%) in SIH-SUS. Of these 3353 records, 1127 CAP cases were present in both databases. Kappa on CAP case identification was 0·72 (95% confidence interval 0·69-0·75). CAP hospitalization incidence using administrative (5285/100 000) and hospital (5054/100 000) primary data were similar (P = 0·184). Our findings suggest that administrative databases of hospitalizations are reliable sources to assess PCV10 impact in time-series analyses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24759601      PMCID: PMC9206775          DOI: 10.1017/S0950268814000922

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  23 in total

1.  Magnitude of the problem of childhood pneumonia.

Authors:  K Mulholland
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

2.  [Hospital Information Systems and their application in public health].

Authors:  Sonia Azevedo Bittencourt; Luiz Antonio Bastos Camacho; Maria do Carmo Leal
Journal:  Cad Saude Publica       Date:  2006-02-06       Impact factor: 1.632

Review 3.  [The development of diagnosis-related groups--DRG's. Methodology for classifying hospital patients].

Authors:  M F Noronha; C T Veras; I C Leite; M S Martins; F Braga Neto; L Silver
Journal:  Rev Saude Publica       Date:  1991-06       Impact factor: 2.106

4.  Bacteriology of community-acquired invasive disease found in a multicountry prospective, population-based, epidemiological surveillance for Pneumococcus in children in Latin America.

Authors:  Ana Lucia Andrade; Adriano Arguedas; Juan Benavides; Ruth Minamisava; Maria-Cristina Cunto de Brandileone; Carolina Soley; Arturo Abdelnour; Ana Laura Jimenez; Elias Jimenez; Sharon Gray; Gail L Rodgers
Journal:  Pediatr Infect Dis J       Date:  2012-12       Impact factor: 2.129

5.  [Hospital admissions forms versus medical records to assess risk of in-hospital death from acute myocardial infarction in Rio de Janeiro, Brazil].

Authors:  Claudia Caminha Escosteguy; Margareth Crisóstomo Portela; Roberto de Andrade Medronho; Mauricio Teixeira Leite de Vasconcellos
Journal:  Cad Saude Publica       Date:  2005-07-11       Impact factor: 1.632

6.  Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Goiânia, Brazil.

Authors:  Ana Lucia Andrade; Renato Oliveira; Maria A Vieira; Ruth Minamisava; Vicente Pessoa; Maria Cristina C Brandileone; Sueli L A Alves; Fernando Alfieri; Rosana Pagliarini; José Cassio Moraes; Sharon Gray; Gail L Rodgers
Journal:  Vaccine       Date:  2011-12-15       Impact factor: 3.641

7.  Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada.

Authors:  Philippe De Wals; Elodie Robin; Elise Fortin; Roseline Thibeault; Manale Ouakki; Monique Douville-Fradet
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

8.  Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

Authors:  Fangjun Zhou; Moe H Kyaw; Abigail Shefer; Carla A Winston; J Pekka Nuorti
Journal:  Arch Pediatr Adolesc Med       Date:  2007-12

9.  Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis.

Authors:  Greice Madeleine Ikeda do Carmo; Catherine Yen; Jennifer Cortes; Alessandra Araújo Siqueira; Wanderson Kleber de Oliveira; Juan José Cortez-Escalante; Ben Lopman; Brendan Flannery; Lucia Helena de Oliveira; Eduardo Hage Carmo; Manish Patel
Journal:  PLoS Med       Date:  2011-04-19       Impact factor: 11.069

Review 10.  Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis.

Authors:  Harish Nair; Eric Af Simões; Igor Rudan; Bradford D Gessner; Eduardo Azziz-Baumgartner; Jian Shayne F Zhang; Daniel R Feikin; Grant A Mackenzie; Jennifer C Moiïsi; Anna Roca; Henry C Baggett; Syed Ma Zaman; Rosalyn J Singleton; Marilla G Lucero; Aruna Chandran; Angela Gentile; Cheryl Cohen; Anand Krishnan; Zulfiqar A Bhutta; Adriano Arguedas; Alexey Wilfrido Clara; Ana Lucia Andrade; Maurice Ope; Raúl Oscar Ruvinsky; María Hortal; John P McCracken; Shabir A Madhi; Nigel Bruce; Shamim A Qazi; Saul S Morris; Shams El Arifeen; Martin W Weber; J Anthony G Scott; W Abdullah Brooks; Robert F Breiman; Harry Campbell
Journal:  Lancet       Date:  2013-01-29       Impact factor: 79.321

View more
  8 in total

1.  Methods and challenges for the health impact assessment of vaccination programs in Latin America.

Authors:  Ana Marli Christovam Sartori; Andréia de Fátima Nascimento; Tânia Yuka Yuba; Patrícia Coelho de Soárez; Hillegonda Maria Dutilh Novaes
Journal:  Rev Saude Publica       Date:  2016-01-15       Impact factor: 2.106

2.  Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children.

Authors:  Sandra Rodrigues da Silva; Luane Marques de Mello; Anderson Soares da Silva; Altacílio Aparecido Nunes
Journal:  Rev Paul Pediatr       Date:  2016-03-30

3.  Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil.

Authors:  Joshua L Warren; Kayoko Shioda; Esra Kürüm; Cynthia Schuck-Paim; Roger Lustig; Robert J Taylor; Lone Simonsen; Daniel M Weinberger
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

4.  Challenges to estimating vaccine impact using hospitalization data.

Authors:  Cynthia Schuck-Paim; Robert J Taylor; Lone Simonsen; Roger Lustig; Esra Kürüm; Christian A W Bruhn; Daniel M Weinberger
Journal:  Vaccine       Date:  2016-11-26       Impact factor: 3.641

5.  Sensitivity of the Dengue Surveillance System in Brazil for Detecting Hospitalized Cases.

Authors:  Giovanini Evelim Coelho; Priscila Leite Leal; Matheus de Paula Cerroni; Ana Cristina Rocha Simplicio; João Bosco Siqueira
Journal:  PLoS Negl Trop Dis       Date:  2016-05-18

6.  Surveillance of the impact of pneumococcal conjugate vaccines in developing countries.

Authors:  Gail L Rodgers; Keith P Klugman
Journal:  Hum Vaccin Immunother       Date:  2015-08-26       Impact factor: 3.452

7.  Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis.

Authors:  Ana Lucia Andrade; Eliane T Afonso; Ruth Minamisava; Ana Luiza Bierrenbach; Elier B Cristo; Otaliba L Morais-Neto; Gabriela M Policena; Carla M A S Domingues; Cristiana M Toscano
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

8.  Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.

Authors:  Adriana Guzman-Holst; Eliana de Barros; Pilar Rubio; Rodrigo DeAntonio; Otavio Cintra; Ariane Abreu
Journal:  Hum Vaccin Immunother       Date:  2021-03-18       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.